Monitor for a subsequent prospectus supplement or takedown announcement under the shelf, which would specify the offering size and terms. The effectiveness itself is a procedural event; the stock impact will depend on whether and when the company actually sells shares.
Price Chart
Executive Summary
Damora Therapeutics' shelf registration (File No. 333-292175) became effective on August 12, 2026, under the Securities Act of 1933. This allows the company to offer and sell securities at its discretion, creating potential dilution overhang for existing common shareholders. The filing is a routine capital markets step for a biotech with a $1.9B market cap, but the effectiveness opens the door for future capital raises that could pressure the stock.
Key Facts
- Shelf registration (File No. 333-292175) declared effective on August 12, 2026.
- Damora Therapeutics is a pharmaceutical preparations company (SIC 2834) with a $1.9B market cap.
- The company was formerly known as Galecto, Inc. and Galecto Inc., with name changes in 2020 and 2016.
- The shelf registration is under the 1933 Securities Act, allowing future securities offerings at the company's discretion.
Financial Impact
No specific offering size or terms disclosed in the EFFECT notice. The shelf registration enables future capital raises, the size and terms of which are unknown.
Risk Factors
- Potential dilution from future share issuance under the shelf registration.
- No specific use of proceeds disclosed, creating uncertainty about capital allocation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002630 |
| Document: 9999999995-26-002630-index.html | 9999999995-26-002630 |
| Document: 9999999995-26-002630.txt | 9999999995-26-002630 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 15d ago | Institutional Cluster | $20.26 | awaiting T+20 | — | $21.96 (+8.42%) |
Sep 28, 2026 29d ago | Insider Buy | $20.75 $21.26 | ▲ +2.46% | ▲ +2.49% | $21.96 (+5.83%) |
Aug 13, 2026 10w ago | EFFECT | $30.73 $28.10 | ▼ −8.56% | ▼ −6.81% | $21.96 (−28.54%) |
Aug 10, 2026 11w ago | Press Release | $30.36 $26.27 | ▲ +13.47% | ▲ +12.41% | $21.96 (+27.67%) |
Jul 20, 2026 14w ago | 8-K | $32.99 $31.80 | ▼ −3.61% | ▼ −6.17% | $21.96 (−33.43%) |
Apr 20, 2026 27w ago | 8-K | $26.82 $24.90 | ▼ −7.16% | ▼ −12.07% | $21.96 (−18.12%) |
Mar 23, 2026 31w ago | Press Release | $23.05 $26.82 | ▲ +16.36% | ▲ +8.94% | $21.96 (−4.73%) |
Mar 19, 2026 31w ago | Press Release | $18.14 $26.43 | ▲ +45.70% | ▲ +36.38% | $21.96 (+21.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers